Cypress Bioscience, Inc. (NASDAQ: CYPB) was up $0.88 (35.2%) this morning on news that hedge fund Ramius has offered to buy the company for $4 a share, totaling approximately $154 million.
Cypress Bioscience, Inc. is a biopharma company that makes drugs for pain, rheumatology, and disorders such as fibromyalgia and rheumatoid arthritis.
